Karolinska Development AB

KDEV

SE0002190926

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Stockholm Other stock markets 11:23:32 2024-04-19 am EDT			5-day change	1st Jan Change
1.518 ^SEK	-0.13%		-2.32%	-10.60%

Apr. 16	Karolinska Development AB Announces That Björn Cochlovius Has Declined Re-Election	CI
Feb. 16	Karolinska Development AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	CI

Rights Issue: 7 new shares @ 4 SEK for 10 existing shares

January 12, 2022

Latest news about Karolinska Development AB

Karolinska Development AB Announces That Björn Cochlovius Has Declined Re-Election	Apr. 16	CI
Karolinska Development AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 16	CI
Karolinska Development Portfolio Company AnaCardio Completes SEK150 Million Funding Round	Jan. 17	MT
AnaCardio AB announced that it has received SEK 150 million in funding from Industrifonden, Karolinska Development AB, Flerie Invest AB	Jan. 16	CI
Karolinska Development Takes Part in Portfolio Company Umecrine Cognition's Capital Raise	Nov. 17	MT
Karolinska Development AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 17	CI
Umecrine Cognition AB announced that it has received SEK 30.4 million in funding from Karolinska Development AB, Ribbskottet AB, Ab Ility Ab and other investors	Nov. 16	CI
Modus Therapeutics to Launch SEK40 Million Rights Offering, Issue Shares to Offset SEK20 Million Loan	Nov. 08	MT
Ossdsign Receives FDA Clearance for the Use of OssDsign Catalyst in Interbody Cages in Spinal Surgery	23-09-19	CI
Karolinska Development AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-25	CI
Karolinska Unit's Investigational Drug Shows Potential as Anemia Treatment	23-05-12	MT
Karolinska Development AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-28	CI
Karolinska Development's Portfolio Company Biosergen Presents Positive Results from Phase 1 Study of Drug Candidate to Treat Systemic Fungal Infection	23-03-13	CI
Karolinska Development AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-17	CI
Karolinska Development AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-17	CI
Karolinska Development AB Announces That Its Portfolio Company Dilafor’S Extended Clinical Phase 2B Study with the Drug Candidate Tafoxiparin Has Resulted in Further Positive Data	23-02-14	CI
Karolinska Development Up 9% as Umecrine Wins US Orphan Drug Tag for Liver Disease Drug Candidate	23-01-17	MT
Karolinska Development AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-18	CI
Karolinska Development Partakes In Danish Dermatology Company Henlez' Seed Financing	22-10-24	MT
Henlez Aps announced that it has received €1 million in funding from Karolinska Development AB, Eir Ventures	22-10-23	CI
Modus Therapeutics AB's Portfolio Company Modus Therapeutics Completes Recruitment in a Clinical Phase 1B Study of Sevuparin	22-09-27	CI
AnaCardio AB announced that it has received SEK 150 million in funding from Industrifonden, Karolinska Development AB, Flerie Invest AB, and other investors	22-09-06	CI
Karolinska Development Appoints New CFO	22-09-06	MT
Karolinska Development AB Announces Chief Financial Officer Changes	22-09-06	CI
Karolinska Development Portfolio Company Recruits First Patient for Pediatric Trial for Malaria Treatment	22-09-02	MT

Chart Karolinska Development AB

Duration

Period

More charts

Karolinska Development AB is a Sweden-based investment company. The Company provides capital to biotechnology firms, as well as develops and commercializes biotechnological products. Its activities are involved in a range of areas: oncology, infections and wound healing, womenâs health, cardiovascular and hematology, medical equipment, diagnostics, pharmaceutical formulation, as well as implants, among others. The Companyâs pharmaceuticals portfolio comprises: AXL1717 for non-small-cell lung carcinoma (NSCLC), APR-246 for ovarian cancer, Sevuparin for malaria, SHACT for pain relief at hysteroscopy and intrauterine device (IUD) insertion, and PC-mAB for acute coronary syndrome (ACS), among others. Furthermore, the Company controls a number of subsidiaries, such as Avaris AB, HBV Thernostica AB, KD Incentive AB, KDev Oncology AB and Limone AB.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-04-26 - Q1 2024 Earnings Release

More about the company

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
KAROLINSKA DEVELOPMENT AB	-10.60%	37.54M
ABBOTT LABORATORIES	-2.65%	183B
MEDTRONIC PLC	-3.57%	105B
DEXCOM, INC.	+5.73%	51.77B
CENCORA, INC.	+16.66%	47.29B
HOYA CORPORATION	-1.73%	40.2B
WEST PHARMACEUTICAL SERVICES, INC.	+6.64%	27.62B
METTLER-TOLEDO INTERNATIONAL, INC.	-1.42%	25.51B
TERUMO CORPORATION	+9.84%	24.73B
ZIMMER BIOMET HOLDINGS, INC.	-1.88%	24.52B

Other Medical Equipment, Supplies & Distribution

Karolinska Development AB

Equities

KDEV

SE0002190926

Medical Equipment, Supplies & Distribution

Rights Issue: 7 new shares @ 4 SEK for 10 existing shares

Latest news about Karolinska Development AB

Chart Karolinska Development AB

Company Profile

Income Statement Evolution

EPS Revisions

Annual profits - Rate of surprise

Sector Other Medical Equipment, Supplies & Distribution